Capricor Therapeutics (CAPR) reported a Q4 loss late Thursday of $0.62 per diluted share, wider than a loss of $0.16 a year earlier.

Analysts polled by FactSet expected a loss of $0.55.

The company reported no revenue for the quarter ended Dec. 31, compared with $11.1 million a year earlier.

Analysts surveyed by FactSet expected $500,000.

The company said its available cash, cash equivalents and marketable securities of $318.1 million as of the end of 2025 will be enough to cover expenses and capital requirements into 2027.

Shares of Capricor Therapeutics were down 2.2% in after-hours activity.